A Story That Starts With a Phone Call Nobody Wants to Get
On November 7, 2025, the FDA called ByHeart, a fast-growing “next-generation” infant formula company, with news no formula maker wants to hear: federal health authorities were investigating an estimated 83 cases of infant botulism reported nationwide since August, and 13 of the affected infants had, at some point, consumed ByHeart formula. Within a day, ByHeart issued a voluntary recall of two specific batches, framing it, in the company’s own words, as an “abundance of caution” move. The FDA, for its part, was careful to note at that early stage that it had not yet identified a direct link between any specific formula and the illnesses — and, notably, observed there was no historical precedent of infant formula ever causing infant botulism. That caveat would not survive the next two weeks.
From Two Batches to Every Can on the Shelf
By November 11, four days after that first phone call, ByHeart’s own internal testing had confirmed something far more serious: Clostridium botulinum, the bacterium behind the illness, in actual samples of its formula. The recall expanded immediately and completely — every can, every single-serve Anywhere Pack, every batch of ByHeart Whole Nutrition Infant Formula, pulled from the market entirely. By November 19, the case count had climbed to 31 infants across 15 states with confirmed exposure to ByHeart formula. By the time investigators finished their work, the final tally reached 51 total cases across 19 states — 28 confirmed and 20 probable, after a handful of initially suspected cases were later ruled out. Every single one of the 48 infants ultimately included in the CDC’s case count required hospitalisation and treatment with BabyBIG, the specific medication used to treat infant botulism. This wasn’t a minor labeling issue or a precautionary measure. It was a genuine, multistate public health emergency involving the most vulnerable population imaginable.
The Part That Should Worry Every Parent: Retailers Kept Selling It
Here’s the detail that turned a contamination story into a regulatory accountability story. Despite the nationwide recall beginning in early November, the FDA found ByHeart formula products still sitting on shelves at more than 175 retail locations across 36 states as late as three weeks after the recall began. The agency’s response was unusually pointed for a federal regulator: it issued formal warning letters directly to Target, Walmart, Kroger, and Albertsons, calling out their specific failure to remove recalled product from store shelves despite having been notified. The FDA went further still, publicly reminding the entire food industry of its legal obligations under the Federal Food, Drug, and Cosmetic Act regarding recalls, specifically for products serving infants and young children — and noted this wasn’t even the first time it had needed to send a similar letter, having issued a comparable warning to a retailer over recalled lead-contaminated fruit puree pouches the year before. A senator demanded answers directly from ByHeart. This had become, very publicly, about more than one company’s manufacturing process.
Chasing the Root Cause: A Genetic Match, and Then a Dead End
The investigation into exactly how contamination occurred has been a genuine, months-long forensic effort — and it still isn’t fully resolved. On January 23, 2026, according to ByHeart’s own public timeline, the FDA shared what the company itself called a meaningful step forward: a genetic match between Clostridium botulinum Type A found in ByHeart’s formula and a sample taken from Organic Whole Milk Powder collected from one of its third-party ingredient suppliers — strong evidence pointing the investigation toward the supply chain rather than ByHeart’s own manufacturing floor. But the story took an unexpected turn on June 3, 2026, when the FDA announced it had completed onsite inspections of ByHeart’s own facilities and did not identify any deficiencies that could explain the root cause of the outbreak. The agency confirmed it remains focused on the powdered milk ingredient from that third-party supplier — meaning that, more than six months after the first phone call, the precise mechanism of contamination is still not fully nailed down, even as the outbreak itself was officially declared over by the CDC back on February 26.
A Company Trying to Rebuild Trust in Public, in Real Time
To ByHeart’s credit, the company has handled its public communications with an unusual level of transparency for a crisis of this scale — publishing a detailed, dated timeline directly on its own website, complete with each new finding as it emerged. The company has laid out what it calls an Action Plan covering new Clostridium botulinum-specific testing protocols, tightened supplier and ingredient quality controls, manufacturing and facility upgrades, and the creation of an independent Food Safety Advisory Council — all framed as the path toward what it describes as the safe resumption of production, in ongoing cooperation with the FDA. Whether that’s enough to win back parents who switched brands mid-crisis remains, naturally, an open question that no corporate timeline can fully answer.
The Bigger Pattern: This Keeps Happening
If 2026’s ByHeart crisis feels familiar, that’s because it is. The U.S. infant formula market is still living in the shadow of the catastrophic 2022 shortage, triggered by contamination at an Abbott Nutrition facility that forced a major plant shutdown and left store shelves bare nationwide. That crisis was severe enough that Congress commissioned an independent study by the National Academies of Sciences, Engineering, and Medicine specifically examining supply, competition, and regulation in the U.S. formula market. The National Academies’ resulting report reached an uncomfortable conclusion: the FDA simply doesn’t have enough authority to prevent these crises from recurring. Its recommendations were specific and, frankly, overdue — give FDA the power to remotely access manufacturer records during a crisis, require companies to give advance notice before discontinuing a formula likely to cause shortages, and establish an automatic “trigger rule” that would suspend tariffs and quotas on imported formula the moment a meaningful market disruption occurs. The ByHeart outbreak landed directly into a system that regulators had already flagged, in writing, as structurally under-equipped to handle exactly this kind of event.
The Quiet Fix: Letting European Formula In Faster
One genuinely useful, if under-discussed, response has been regulatory rather than legislative. On May 19, 2026, the FDA published updated guidance streamlining certification for European-manufactured formulas, expected to shave two to three weeks off import delays for established European brands like HiPP, Holle, Kendamil, and Lebenswert — formulas that had spent years stuck in a kind of regulatory grey zone, popular with parents but cumbersome to import legally at scale. The practical effect by late spring 2026 was a market with genuinely more resilience baked in: when ByHeart-loyal parents needed an alternative during the recall, brands like Kendamil and HiPP Dutch were positioned, for the first time, to absorb that demand at real scale — with Kendamil expanding its retail footprint to more than 2,400 Target locations, up from 1,800 just months earlier. It’s a small, technical-sounding policy change. It also may be the single most concretely useful thing regulators did all year to make the next shortage less painful than the last one.
Where This Leaves the Industry
Constancy Researchers’ honest assessment: the infant formula market in 2026 is being reshaped less by any single dramatic policy overhaul and more by the accumulated weight of two consecutive crises in four years, each exposing a slightly different structural weakness — manufacturing concentration in 2022, supply chain ingredient traceability in 2025 and 2026. The genuine bright spots are real: faster European import pathways, a higher bar for supplier-level testing that ByHeart and likely its competitors will now adopt voluntarily, and a Congress that, per the April 29 hearing, is finally treating infant formula oversight as part of the same legislative conversation as broader food safety reform, rather than a one-off crisis response. But the honest, slightly uncomfortable truth is that the root cause of the most recent outbreak still isn’t fully solved, six months and one completed plant inspection later. For an industry feeding the most vulnerable consumers in the entire food system, “mostly resolved, investigation ongoing” is a genuinely strange place to still be standing in mid-2026.
Looking to navigate geopolitical risks and identify new industry opportunities?
Connect with Constancy Researchers for data-driven insights, geopolitical intelligence, and strategic consulting tailored to your business needs.
